APA (7th ed.) Citation

C, Z., J, L., T, G., X, M., X, C., J, Z., . . . Y, W. (2025). Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: Mechanism and safety evaluation. Breast cancer research and treatment, 211(3), 637. https://doi.org/10.1007/s10549-025-07676-9

Chicago Style (17th ed.) Citation

C, Zhang, Liu J, Gu T, Meng X, Cai X, Zhang J, Chen Y, Zhang D, and Wu Y. "Enhanced Antitumor Efficacy of Bispecific Antibody Blocking PD-L1 and LAG-3 with Doxorubicin: Mechanism and Safety Evaluation." Breast Cancer Research and Treatment 211, no. 3 (2025): 637. https://doi.org/10.1007/s10549-025-07676-9.

MLA (9th ed.) Citation

C, Zhang, et al. "Enhanced Antitumor Efficacy of Bispecific Antibody Blocking PD-L1 and LAG-3 with Doxorubicin: Mechanism and Safety Evaluation." Breast Cancer Research and Treatment, vol. 211, no. 3, 2025, p. 637, https://doi.org/10.1007/s10549-025-07676-9.